New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:08 EDTARWRArrowHead Research publishes results regarding company's Dynamic Polyconjugate
Arrowhead Research announced the publication of data demonstrating that high level target gene knockdown with low doses of cholesterol-siRNA is possible in non-human primates using the company's Dynamic Polyconjugate delivery system and a novel co-injection strategy. This new delivery approach dramatically increases the efficacy of cholesterol-siRNA and, together with the co-injection strategy, simplifies the manufacturing process to enable a commercially scalable delivery vehicle for RNAi therapeutics. The company is using this strategy and a next generation DPC polymer in ARC-520, its hepatitis B clinical candidate. The paper titled, "Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated siRNAs in vivo," was published online ahead of print in the journal Nucleic Acid Therapeutics to be featured in the December issue
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:37 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 15, 2015
10:20 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
May 14, 2015
10:56 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
11:08 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 12, 2015
10:16 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
May 11, 2015
16:09 EDTARWRArrowhead reports Q2 EPS (51c), consensus (34c)
Reports Q2 revenue $43,750, consensus $110,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use